INTRODUCTION
Bone marrow (BM) fibrosis is characterized by the increased deposition of reticulin fibers or collagen fibers. A number of hematologic and non-hematologic disorders are associated with increased BM fibrosis (Kuter et al., 2007) , which is a central pathological feature and World Health Organization major diagnostic criterion of myelofibrosis (MF) . MF refers to BCR-ABL1-negative myeloproliferative neoplasms (MPNs) (Tefferi et al., 2007) . The majority of patients with MF carry mutations that activate JAK-STAT signaling; 60% of patients with MF harbor the JAK2V617F mutation, $30% carry a calreticulin mutation (CALR), and 8% carry a myelo-proliferative leukemia virus oncogene (MPL) mutation (Klampfl et al., 2013; Levine, 2012; Levine and Gilliland, 2008; Nangalia et al., 2013; Tefferi et al., 2014) . Primary myelofibrosis (PMF) is the least common of the three classic MPNs; however, it is the most aggressive and is associated with a significantly shortened survival (Mehta et al., 2014; Tefferi, 2011) . PMF is characterized by malignant clonal hematopoiesis, BM fibrosis, extramedullary hematopoiesis, splenomegaly, and abnormal cytokine expression leading to significant systemic symptoms, risk of transformation to acute leukemia, and reduced survival.
Although the somatic mutations that drive the development of MPN have been largely defined, the cellular targets of BM fibrosis still remain obscure. In MPN, mesenchymal stromal cells (MSCs), key components of the hematopoietic stem cell (HSC) niche, have recently been shown to acquire a secretory, extracellular matrix remodeling phenotype and lose their hematopoiesis-supporting capacity (Schneider et al., 2014) . A recent study using a knockin Jak2V617F MPN mouse model demonstrated that MPN progression in the bone marrow creates neuropathic changes in the BM niche, which affect the activity of perivascular MSCs and alter the function of the HSC niche (Arranz et al., 2014) . Identifying the cells that drive the development of a fibrotic BM niche with its detrimental consequences for the maintenance of HSCs is a prerequisite for the development of novel targeted therapeutics.
Multiple genetic-fate-tracing studies have been performed to elucidate the cellular origin of fibrosis driving myofibroblasts in solid organs (Kramann et al., 2013) . The recent identification of perivascular Gli1
+ MSC-like cells as a major cellular origin of organ fibrosis and as a relevant therapeutic target to prevent solid organ dysfunction after injury provides significant potential to identify the origin of fibrosis-driving cells in BM fibrosis (Kramann et al., 2015b; Schepers et al., 2015) . Given that the Hedgehog (Hh) signaling pathway regulates mesenchyme cell fate during development and in view of growing evidence implicating a critical role for Hh in solid organ fibrosis and cancer (Aberger and Ruiz I Altaba, 2014; Kramann et al., 2013) , these findings provide a rationale for potential targeting of the Hh pathway in BM fibrosis.
Currently, the clonal myeloid neoplasm is the primary therapeutic target in MPN, and the only potentially curative therapy for patients with PMF is allogeneic HSC transplantation, a high-risk procedure with significant associated morbidity and mortality. Establishing new modalities to directly block the cellular changes occurring in the malignant BM niche, including the inhibition of aberrant MSC differentiation into fibrosis-driving cells, could have a substantial therapeutic impact in the treatment of BM fibrosis.
RESULTS

Perivascular and Endosteal Localization of Gli1
+ Cells in the BM Niche Having identified Gli1 as a faithful marker for fibrosis-driving MSCs in solid organs (Kramann et al., 2015b) , we sought to characterize Gli1 + cells in the BM niche more thoroughly. Gli1CreER t2 driver mice were crossed to a tdTomato reporter for inducible genetic labeling. Gli1 + cells in the BM either align against bone (Figure 1A) or are associated with the vasculature (Figures 1B and 1C) . Quantification of Gli1 + cell distribution in bigenic Gli1CreER;tdTomato mice indicated that the majority of Gli1 + cells reside in the endosteal niche, whereas a smaller fraction are associated with BM sinusoids and arterioles ( Figure 1D ). Clearing of a sternal bone with deep imaging of the BM further illustrated the endosteal and perivascular localization of Gli1 + cells (Figures S1A and S1B). We next assessed the expression of markers that have been reported for stromal and perivascular cells by immunostaining and confocal microscopy. We observed high CD105 and moderate NG2 expression in perisinusoidal and periarteriolar Gli1 + cells, while expression of both markers was almost absent in endosteal Gli1 + cells . Nestin expression was detected in many endosteal and perivascular Gli1 + cells; however, we also observed Gli1 + cells in both niches that did not co-express nestin ( Figure 1H ). Of note, we did not detect leptin receptor expression in Gli1 + cells ( Figure S1C ).
While we detected sympathic innvervation of periarteriolar and to a lesser extent perisinusoidal Gli1 + cells, endosteal Gli1 + cells did not show adjacent sympathic nerves ( Figure 1I ). Similarly, many perivascular, but not endosteal, Gli1
+ cells were adjacent to Schwann cells ( Figure 1J ). We further studied the surface profile of Gli1 + cells isolated from bone chips of bigenic Gli1CreER;tdTomato mice by flow cytometry. We observed high expression of pericyte markers such as CD73, mesenchymal markers such as platelet-derived growth factor receptor alpha PDGFRa (CD140a), and the mesenchymal stem cell markers CD105, CD44, CD29, Sca1, and CD51, but we did not observe expression of the endothelial cell lineage marker CD31 (Figures 1K and S1D) . To study Gli1 expression in human BM, we validated Gli1 staining in human glioblastoma multiforme tissue that had been EDTA treated ( Figure S1E ). Immunostaining of human BM indicates Gli1 expression in spindle-shaped stromal cells (1) aligning the bone (endosteal niche) or (2) associated with the vasculature ( Figure 1L ). Image quantification of human BM localization demonstrated that 68.1% ± 2.7% of Gli1 + cells are in the endosteal region and 31.9% ± 2.7% are in the perivascular region, which is comparable to the findings in murine BM. Co-staining for nestin and Gli1 indicated co-expression in some, but not all, Gli1-expressing cells ( Figure S1F ), whereas leptin receptor and NG2 were not expressed ( Figure S1F ). When isolated from human BM, Gli1 + cells express CD90, CD105, and nestin, consistent with their pericyte/MSC origin (Figures 1M and S1G) .
Gli1 + Cells Are Myofibroblast Precursors in MF
To determine if Gli1 + cells have a fibrosis-inducing role in BM fibrosis, we performed genetic-fate-tracing experiments in a murine model of thrombopoietin (ThPO)-induced MF (Villeval et al., 1997; Yan et al., 1996) . To trace the fate of Gli1 + cells, bigenic Gli1CreER t2+/À ;tdTomato +/À recipient mice received tamoxifen to induce cell-specific expression of the tdTomato fluorochrome and were subjected to lethal irradiation followed by transplantation of ThPO-overexpressing or control BM (Figures 2A and 2B ). We transduced hematopoietic stem and progenitor cells from (E-H) CD105, NG2, and nestin expression by Gli1 + cells in the endosteal, perisinusoidal, and periarteriolar niche (mean ± SEM). Arrows indicate co-expression in Gli1 + cells, and arrowheads indicate no expression in Gli1 + cells. Scale bars represent 50 mm in (E) and (F) and 25 mm in (G) and (H).
(I) Representative z stack images and quantification of Gli1 + cell innervation by tyrosine hydroxylase (TyrHydr)-positive sympathic nerve fibers (mean ± SEM). See also Figure S1 . (B) Experimental design: bigenic Gli1CreER;tdTomato mice were injected with tamoxifen (3 3 10 mg p.o.) at 8 weeks of age, lethally irradiated at 10 days after the last tamoxifen dose, and received c-kit-enriched HSCs from WT littermates expressing either thrombopoietin cDNA (ThPO; n = 5, three males) or control cDNA (control, n = 5, three males; both lentiviral SFFV-iGFP vector backbone Figure S2D ). Trichrome staining indicated marked remodeling of the spleen, but without development of collagen fibrosis ( Figure S2E ). Figure 2H ). Quantification of Gli1 + cell distance to bone and endothelial cells by image analysis showed that Gli1 + cells are mobilized from their endosteal and perivascular niche ( Figure 2I ). Figure 3G ). Genetic ablation of the Gli1 + cell population also reduced the fibrotic readouts a-SMA, collagen 3a1 (Col3a1), and fibronectin ( Figures 3H-3J ), which were all significantly increased following ThPO overexpression in the BM. These experiments provide the first in vivo functional evidence that Gli1 + cells are fibrosis-driving cells in BM fibrosis and represent a novel cellular target. Importantly, the ablation of Gli1 + cells in normal hematopoiesis (control + DTX) did not have detrimental effects on differentiated lineages ( Figures S3D-S3H ) or HSPCs ( Figure 3K ). Furthermore, we did not observe a significant effect of Gli1 + cell ablation on marrow vascularization (CD31 surface area), sympathic nerve fibers (tyrosine hydroxylase surface area), or glia cells (GFAP surface area) ( Figures S3I-S3K ). Figure S2 .
proteins (Lauth et al., 2007) and is a promising treatment of fibrosis in lung and kidney (Kramann et al., 2015a; Moshai et al., 2014 ;tdTomato mice received tamoxifen (3 3 10 mg p.o.) and were lethally irradiated 10 days after the last tamoxifen dose and transplanted with 2 3 10 5 c-kit purified BM cells from WT littermates that had been transduced with either control (n = 10) or Jak2(V617F) (n = 10) cDNA (both MCSV-IRES-GFP retroviral backbone vector). Mice were injected with GANT61 (50 mg/kg body weight) or vehicle (corn oil/ethanol) every other day between 8 and 17 weeks after transplantation (control + vehicle n = 3, two males; control + GANT61 n = 5, three males; Jak2(V617F) + vehicle n = 4, three males; Jak2(V617F) + GANT61 n = 4, three males). (legend continued on next page) mice received tamoxifen and were transplanted with BM of WT littermates retrovirally transduced with either WT Jak2 control vector or Jak2(V617F). Treatment with either GANT61 or vehicle was initiated at 8 weeks after onset of the disease in the Jak2(V617F) group ( Figures 4A and S4A ). Mice were randomized based on Hb levels to receive either GANT61 or vehicle every other day.
Mice transplanted with Jak2(V617F) had significantly elevated Hb levels compared to the control groups ( Figure S4A ), reflecting erythroid hyperplasia, while treatment with GANT61 rescued this phenotype with a significant decrease in Hb to levels comparable to the control groups. Analysis of BM at 17 weeks after transplantation showed a significant expansion of genetically tagged Gli1 + cells with development of reticulin fibrosis and splenomegaly ( Figures 4B-4F + cell mobilization from both the endosteal and the perivascular niche, which was ameliorated by GANT61 treatment (Figures S4D and S4E) .
Moreover, while Jak2(V617F) transplantation resulted in significantly increased spleen weight and numbers of long-term HSCs (LT-HSCs), multipotent progenitor cells (MPPs), and erythroid progenitors, as is typical for polycythemia vera (PV), GANT61 reversed this phenotype ( Figures 4G, S4F , and S4G) suggesting an effect of GANT61 on both Gli1 + cells and the malignant hematopoietic clone. To assess the relative effect of GANT61 treatment on Jak2(V617F)-expressing hematopoietic cells, we treated transduced (GFP + ) and non-transduced (GFP À ) c-kit + HSPCs in vitro. GANT61 specifically reduced Jak2(V617F)-expressing cells and induced significant apoptosis (Figures 4H and S4H) . We analyzed the downstream effects of Jak2(V617) and observed a significant downregulation of STAT5 phosphorylation by GANT61 treatment ( Figure 4I ). Jak2(V617F) induced expression of the phosphatidylinositol-3-kinase (PI3K), which was also inhibited by GANT61 treatment ( Figure 4J ). As the PI3K/Akt axis was shown to activate Gli in a non-canonical fashion, we analyzed Akt and Gli1 expression. Jak2(V617F) in HSPCs induced increased (but not significant) expression of both Akt and Gli1, which had a tendency to be decreased by GANT61 treatment ( Figure 4J ). These data suggest that targeting Gli proteins by GANT61 is a novel therapeutic approach in MF that affects the expansion of both MF-driving Gli1 + myofibroblasts and the malignant hematopoietic clone. (Bares and Ge, 2015) . We found upregulated pathways that play a critical role not only in cytokine-cytokine receptor interaction but also in the inflammatory response, specifically the leukotriene (LOX) and prostaglandin (COX) pathways, both of which use the same primary precursor, arachidonic acid ( Figures 5C and S5 ). There is evidence that BM stromal cells actively metabolize arachidonic acid and that metabolites are important for the regulation of hematopoiesis (Abraham et al., 1991) . Differential gene expression analysis demonstrated that megakaryocyte-associated genes were significantly upregulated, in particular the chemokine Cxcl4 (cytokine-cytokine receptor interaction pathway; Figures 5C and 5D) , which has been implicated to play a role in fibrosis (Burstein et al., 1984; van Bon et al., 2014; Zaldivar et al., 2010) and HSC regulation (Bruns et al., 2014) . In addition, we identified Cxcl4 among 4 upregulated cytokines in a cytokine array from medium supernatant of both ThPO and Jak2(V617F)-overexpressing HSPCs ( Figure 5E ). In line with previous studies of niche cells in BM fibrosis (Schepers et al., 2013), we found altered expression of many HSC-regulatory genes and cytokines, including a broad See also Figure S4 .
Gli1
downregulation of HSC retention factors, particularly Cxcl12 (Figures 5C and 5F). We further observed increased metabolic activity in Gli1 + stromal cells in BM fibrosis ( Figure 5C ), particularly in fatty acid metabolism. PPARy, the master switch of lipogenic differentiation in MSCs, was further significantly induced in BM fibrosis and was recently described to play a role in pulmonary fibrosis (El Agha et al., 2017) . To identify a potential lipogenic phenotype of Gli1 + MSCs in BM fibrosis, we performed co-staining with the neutral lipid stain (LipidTOX). We observed sparsely LipidTOXpositive Gli1 + cells in BM from ThPO-overexpressing mice ( Figure 5G ).
Based on previously published data and our findings, we propose a model of abnormal release of Cxcl4 from a-granules from atypical megakaryocytes and platelets in MPN (Vannucchi et al., 2005) ( Figure 5H ). In turn, Cxcl4 as a CXC chemokine contributes to the activation of Gli1 + cells and their transdifferentiation into a-SMA + myofibroblasts and later to expression of Cxcl4 in Gli1 + cells. In fibrosis progression, thrombin and collagen contribute to the activation of arachidonic acid metabolism, which transforms stromal cells into inflammatory, metabolically active cells that lose their hematopoiesis-supporting capacity, further contributing to abnormal hematopoiesis in MPN ( Figure 5H ). To validate the RNA-sequencing findings and dissect the direct interaction of stromal cells and hematopoietic cells in BM fibrosis in vitro, we co-cultured ThPO-overexpressing c-kit + HSPCs and Gli1 + isolated stromal cells. As GANT61 ameliorates BM fibrosis, we further tested the effect of GANT61 treatment on differentially expressed genes ( Figure 6A ). The co-culture with ThPO overexpressing HSPCs significantly induced expression of Cxcl4 in stromal cells, which was completely normalized by GANT61 treatment. Endothelin 1 and MMP9 as pro-fibrotic readouts associated with increased Cxcl4 expression in organ fibrosis (van Bon et al., 2014) , were significantly upregulated in stromal cells exposed to ThPO overexpressing HSPCs and were normalized after GANT61 treatments (Figure 6A) . ALOX12 and PPARy as targets of activated arachidonic acid were upregulated in stromal cells in the presence of ThPO overexpressing HSPCs and normalized by GANT61 treatment.
As previous studies suggested that GANT61 leads to apoptosis and cell cycle arrest, we analyzed the anti-apoptotic gene Bcl2 and the cyclin-dependent kinase inhibitor p21. Bcl2 was significantly decreased after treatment with GANT61 and p21 significantly induced, suggesting that GANT61 induces apoptosis and might affect cell-cycle ( Figure 6A ). We validated in co-culture experiments that the exposure of Gli1 + cells with ThPO overexpressing HSPCs induces differentiation into a-SMA + myofibroblasts and that GANT61 inhibits the differentiation or induces apoptosis in differentiated cells (Figure 6B) . We analyzed apoptosis in Gli1 + and Gli1 À stromal cells and confirmed that GANT61 induces apoptosis specifically in Gli1 + stromal cells ( Figure 6C ). GANT61 further induced apoptosis in hematopoietic cells, suggesting that part of the positive effect of GANT61 in BM fibrosis can be explained by reduction of the malignant hematopoietic clone ( Figure 6D ). Interestingly, we observed a direct effect of GANT61 on megakaryocyte ploidy, suggesting inhibition of megakaryocyte maturation (Figures 6E and S6) . These data further validate that GANT61 affects both Gli1 + stromal cells and the malignant hematopoietic clone.
Cxcl4 Is Necessary and Sufficient for the Migration of Gli1 + Stromal Cells and Induces Their Myofibroblastic Differentiation To confirm that Cxcl4 induces migration and myofibroblastic differentiation of Gli1 + cells, we exposed Gli1 + cells to recombinant Cxcl4 and analyzed myofibroblast differentiation and cell migration toward a Cxcl4 gradient. Recombinant Cxcl4 (rCxcl4) significantly induced myofibroblast differentiation of Gli1 + cells comparable to induction with transforming growth factor b (TGF-b), a known stimulus for differentiation of MSCs into myofibroblasts ( Figure 6F ). In a chemotactic migration assay, Cxcl4 significantly increased the migration of Gli1 + cells toward the rCxcl4 gradient ( Figure 6G ). Having established that Cxcl4 induces migration and myofibroblast differentiation of Gli1 + cells, we sought to confirm the hypothesis that Cxcl4 in hematopoietic cells in BM fibrosis induces the migration and differentiation process of Gli1 + stromal cells. We tested if genetic knockout of Cxcl4 in hematopoietic cells can ameliorate the migration and myofibroblastic differentiation of Gli1 + cells. We performed a migration assay with Gli1 + cells on a transwell membrane and hematopoietic cells isolated from Cxcl4 À/À mice and WT controls, expressing control or ThPO cDNA, in the lower compartment as a chemotactic gradient ( Figure 6H ). The migration of Gli1 + cells was significantly increased in the presence of ThPO-overexpressing cells and Bigenic Gli1CreER;tdTomato mice were injected with tamoxifen (3 3 10 mg p.o.) at 8 weeks of age, lethally irradiated at 10 days after the last tamoxifen dose, and received c-kit enriched HSCs from WT littermates expressing either thrombopoietin cDNA (ThPO; n = 5, three males) or control cDNA (control, n = 4, three males; both lentiviral SFFV-iGFP vector backbone). Mice were sacrificed at 70 days after transplantation. Gli1 + cells were sort purified as lin Figure 6H ). We next analyzed whether the genetic knockout of Cxcl4 in hematopoietic cells had an effect on Gli1 + myofibroblasts in a direct co-culture model. The absence of Cxcl4 in hematopoietic cells ameliorated myofibroblastic differentiation, but did not completely inhibit the differentiation process ( Figure 6I ), indicating that myofibroblastic differentiation results from multiple cytokines secreted by the hematopoietic clone. In summary, these data show that Cxcl4 in the hematopoietic clone is a strong chemotactic factor and contributes to fibrotic transformation.
+ Cells Expand in Human MPN and Can Be Targeted Therapeutically Given that Gli1 + cells are important myofibroblast progenitors and show efficacy as a therapeutic target in two distinct mouse models of MF, we next asked whether the same pathway is active in human MF. BM punch biopsy specimens were collected from MPN patients (n = 60) and age-matched, normal BM biopsy specimens without a primary hematological disease were collected from healthy controls (n = 33). Specimens were stained for reticulin and scored blindly by pathologists for the severity of MF and Gli1 expression (Figures 7A and S7A ; Table  S1 ). Gli1 + cells aligned the bone and sinusoids in healthy controls as demonstrated in Figure 7A . Comparable to the findings in murine MPN models, the frequency of spindle-shaped Gli1 + cells significantly increased in MPN ( Figures 7A and 7B ). Gli1 + cells
were diffusely present in the hematopoietic marrow, and their localization was not restricted to the endosteal and vascular niche. Gli1 + cells were found in cellular areas or positioned within amorphous matrix deposits ( Figure 7A ). The frequency of Gli1 + cells positively correlated with an increase in reticulin grading of MF, independent of the MPN classification ( Figure 7C ). The frequency of Gli1 + cells did not correlate with JAK2(V617F) or calreticulin gene (CALR) mutation status ( Figure S7B ), suggesting a common pathobiological pathway that regulates the interactions among the malignant hematopoietic clone, atypical megakaryocytes, and their niche. Next, we isolated MSCs from BM biopsy specimens of MPN patients (MPN-MSC; n = 4) and healthy control donors (n = 4). Interestingly, we observed upregulation of both Gli1 and a-SMA mRNA in MSCs from MPN patients when compared to MSCs of healthy donors, as observed in murine models ( Figure 7D) . MSCs from MPN patients also upregulated mRNA expression of extracellular matrix proteins such as collagens and fibronectin ( Figure 7D ). Cells with myofibroblast morphology were only observed in MPN, as shown by staining of a-SMA + stress fibers ( Figure 7E ), a-SMA gene expression ( Figure 7F ), and an a-SMA population by flow cytometry ( Figure 7G ). Strikingly, treatment with GANT61 significantly reduced both a-SMA and Gli1-expression in MPN-MSCs at the protein and gene expression levels ( Figures 7F and 7G ). We observed a significant increase in apoptosis (AnnexinV + 7AAD À ) specifically in MPN-MSCs treated with GANT61 ( Figure 7H ). These results suggest that GANT61 induces apoptosis in Gli1-expressing myofibroblasts. Expression of the MSC marker nestin has been shown to be significantly reduced in MPN (Arranz et al., 2014) . We asked how Gli1 and nestin expression are related in myelofibrotic transformation. Flow cytometry confirmed that Gli1 cells express nestin under steady-state conditions and that nestin expression is lost in MPN, whereas Gli1 expression is increased, indicating that Gli1 promotes the myelofibrotic transformation ( Figure 7I ). In summary, these data suggest that targeting Gli1 + MSCs by GANT61 might be a potential novel therapy in human BM fibrosis.
DISCUSSION
Our studies strongly suggest a critical role for Gli1 + stromal cells in the pathogenesis of BM fibrosis. Genetic ablation and pharmacological targeting of Gli1 + cells in two mouse models of BM fibrosis/MF and in human samples reversed the myofibroblast phenotype and matrix production, two central mechanisms in the progression of BM fibrosis.
Most investigators agree that myofibroblasts cause fibrosis across different organ systems, although the functional contribution of myofibroblasts in BM fibrosis remained unclear. Electron microscopy studies from the last century suggested an increase of myofibroblasts in human BM fibrosis (Biagini et al., 1985; Thiele et al., 1991 Figure S1C ). The majority of Gli1 + cells in the endosteal niche were not associated with GFAP + glia or sympathic nerve fibers and only partially expressed nestin. Thus, these cells might be partially distinct from the reported nestin + populations. Gli1 + cells have trilineage (multipotent) differentiation potential, including osteogenic differentiation (Kramann et al., 2015b) . A subpopulation of Gli1 + MSCs expresses CD51 (and Sca1 low ), the marker combination for OBCs. Schepers et al. See also Figure S7 and Tables S1 and S2 (Burstein et al., 1984) . A central role of Cxcl4 in fibrosis was confirmed in solid organs, and it was demonstrated that Cxcl4 is not only secreted by activated platelets but also plasmacytoid dendritic cells and fibroblasts (van Bon et al., 2014; Zaldivar et al., 2010) . We demonstrated that Cxcl4 in MPN HSPCs induces migration of Gli1 + stromal cells and myofibroblastic differentiation. We further observed significant downregulation of the chemokine stromal cellderived factor 1 (SDF-1) (CXCL12), in line with previous studies characterizing niche cells in MPN (Arranz et al., 2014; Schepers et al., 2013) . Deletion of Cxcl12 in stromal cells was shown to increase circulating platelets (Arranz et al., 2014; Tzeng et al., 2011) . Based on our data and previous studies, we propose that Gli1 + stromal cells are activated from their niche by atypical platelets/megakaryocytes (mediated by Cxcl4), which leads to a cascade of myofibroblastic differentiation, metabolic reprogramming, and downregulation of CXCL12.
Currently, the standard therapies used to treat MF can be divided into two categories: clonal eradication or targeting BM fibrosis. In PMF, the only therapy with a curative potential is allogenic HSC transplantation (Rondelli et al., 2005) . With the introduction of selective JAK inhibitors over the last 10 years, initial expectation of clonal suppression as measured by elimination of molecular and karyotypic abnormalities was dampened by the observations of persistent clonal hematopoiesis and unaltered MPN BM pathological features. Although JAK inhibitors have been shown to improve patient constitutional symptoms and reduce splenomegaly, JAK inhibitor monotherapy does not significantly reduce mutant allele burden in the majority of MPN patients (Harrison et al., 2012 (Harrison et al., , 2016 Verstovsek et al., 2012) .
The therapeutic window for JAK inhibitors is limited due to the essential role of the JAK-STAT signaling pathway in normal hematopoiesis, which has been observed in the clinic, where these inhibitors have been associated with dose-limiting toxicities. Therefore, there is a need to identify additional pathways that might be involved in the development and maintenance of MPN mutant clones, which could be targeted in combination with JAK2 for improved therapeutic benefit.
An increase in the expression of Hh target genes has been observed in granulocytes isolated from MPN patients (Bhagwat et al., 2013) . So far, the exact role of the Hh pathway in MF and its contribution to BM fibrosis is not fully understood. Here, we show that Gli1-expression is significantly increased in stromal cells from MPN patients and that Gli1 + MSCs are activated from their niche in the BM upon expansion of the malignant clone and migrate into the hematopoietic marrow, where they differentiate into matrix-producing myofibroblasts. Combinations of JAK2 inhibitors with inhibitors of the Hh pathway could provide an avenue of targeting stem cell-derived clonal myeloproliferation (which evades JAK2-targeted monotherapy). Preclinical and clinical data suggest that Hh pathway inhibitors have therapeutic activity in MF. To date, only smoothened (SMO) inhibitors have been tested in MF, with varying success (Sasaki et al., 2015) . We hypothesize that Gli proteins in Gli1 + cells can be activated independent of canonical Hh signaling, explaining the mixed response in patients with MF (e.g., by PI3K/AKT signaling). Our data provide a rationale for the use of Gli1 + cells for targeted therapy in BM fibrosis, either as monotherapy or in combination with other agents.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: CONTACT FOR REAGENT AND RESOURCE SHARING As Lead Contact, Rebekka K. Schneider (Erasmus Medical Center, Rotterdam) is responsible for all reagent and resource requests. Please contact Rebekka K. Schneider at r.k.schneider@erasmusmc.nl with requests and inquiries.
STAR+METHODS KEY RESOURCES TABLE
EXPERIMENTAL MODEL AND SUBJECT DETAILS Mice
All mouse experiments were approved by the responsible institutional and governmental ethics board i.e., Animal Care and Use Committee at Harvard University and Boston Childrens Hospital and the German government authorities (Landesamt f€ ur Natur, Umwelt und Verbraucherschutz Nordrhein Westfalen). Gli1CreER t2 (i.e., Gli1 tm3(re/ERT2)Alj/ J, JAX Stock #007913), Rosa26tdTomato (i.e., B6-Cg-Gt(ROSA)26Sort tm(CAG-tdTomato)Hze /J JAX Stock # 007909) and iDTR mice (i.e., C57BL/6-Gt(ROSA)26Sor tm1(HBEGF)Awai /J, JAX Stock # 007900) were purchased from Jackson Laboratories (Bar Harbor, ME, USA). Offspring were genotyped by PCR according to the protocol from the Jackson laboratory. Males and females were used for the experiments as stated in the figure legends. Animals were maintained on the same 12hr light-dark cycle and received water and standard chow at libitum. For lineage tracing studies, 6-7 week old mice received 3x10 mg tamoxifen in corn oil / 3% ethanol (Sigma) via oral gavage 10 days before lethal irradiation (1050 Rads). Mice received 5x10 5 cells from 8 week old WT littermates that had been harvested 48 hr prior to transplantation and were transduced with (1) Jak2(V617F) (JAK2) or control (control; WT Jak2) cDNA retrovirus or (2) ThPO or control (empty vector) lentivirus. Mice were randomly assigned to groups by choosing from a list of animal numbers with four digits. Mice were sacrificed 8 weeks after BM transplantation in the ThPO fate tracing experiments and 17 weeks after BM transplantation in the JAK2 experiments, when a significant decrease in the hemoglobin counts was observed. For RNA-Sequencing mice were sacrificed 10 weeks after BM transplantation.
For the ablation experiments, bigenic Gli1CreER t2 ; iDTR mice received tamoxifen (3x 10mg per oral gavage) 10 days prior to irradiation and BM transplantation and were injected with diphtheriatoxin dissolved in PBS (List Biological Laboratories) at a dose of 50ng/g body weight intraperitoneally (i.p.) as indicated ( Figure 3B ). Mice were sacrificed 14 weeks after BM transplantation. Mice were equally assigned to DTX or vehicle groups based on their Hb to control for significant differences before start of the treatment (at 4 weeks after BM transplantation). GANT61 Cayman Chemical) was dissolved in ethanol and stored at À80 C. The ethanol solution was further diluted in corn oil (1:4) immediately before injections. Mice were injected with 50mg/kg-body weight of GANT61 (s.c.) or vehicle (corn oil / ethanol) every other day starting 8 weeks after BM transplantation until sacrifice at 119 days after transplantation.
Human specimen
Patients samples originated from RWTH Aachen University Hospital and Hannover Medical School and the study was approved by the Ethical board of the RWTH Aachen Medical Faculty (ethical votes 173/06, 206/09, 300/13, 94/16) and the Hannover Medical School (ethical vote 3381-2016). Samples were deidentified at the time of inclusion. All patients provided informed consent and the study was performed in accordance with the Declaration of Helsinki. BM biopsies for histological examination (tissue microarrays and whole punch biopsies) were chosen from archived patient samples of paraffin-embedded tissue from the Institute of Pathology at RWTH Aachen University Hospital, Aachen, Germany and from the Biobank of Dr. G. B€ usche at the Department of Pathology, Hannover Medical School, Hannover, Germany. Biopsies were primarily taken during earlier hospitalization. Patient characteristics of biopsy specimen are reported in Table S1 . Isolated human MSCs were studied from 4 healthy donors (age 62 ± 10, 2 males) and 4 MPN patients (51 ± 10, 2 males) as outlined in Table S2 . To establish the Gli1 antibody staining, human glioblastoma multiforme tissue was accessed from the RWTH Aachen Biobank.
METHOD DETAILS
Human cell isolation and GANT61 treatment Human MSCs (MPN patients or controls from hip replacement surgeries) were isolated by tissue culture plastic adherence after the mononuclear cell fraction was separated by Ficoll. Cells were seeded at a density of 5x10 6 cells/flask. MSCs were maintained in medium (Mesenpan; PAN Biotech) containing 10% fetal bovine serum (Life Technologies), 1% penicillin-streptomycin-glutamine (Life Technologies). Medium was changed every third day and cells were split at near confluence. MSC surface phenotype was assessed at passage 1 using antibodies against the following antigens: CD45 (clone HI30), CD105 (SN6), CD73 (AD2). Antibodies were purchased from BD Biosciences (San Jose, USA) or eBiosciences (San Diego, USA). To study the effect of GANT61, cells were treated for 24-48h with 10 mM GANT61 (Sigma) in DMSO versus vehicle (DMSO).
Isolation of Gli1
+ cells Gli1 + cells were isolated from the compact bone of 8-10 week old bigenic, male, Gli1CreER;tdTomato mice after receiving 3x10mg
Tamoxifen p.o. Compact bones including femur, tibia, pelvis and vertebrae were crushed by mortar and pestle until only small fragments were left. The fragments were digested at 37 C in 10ml collagenase 2 (1mg/ml, Invitrogen) DMEM (GIBCO) solution with 10% FBS (GIBCO) for 90min. Following digestion the fragments were washed three times with PBS and then transferred to a 15cm cellculture dish. The bone chips were cultured in alpha MEM (GlutaMAX, Life Technologies) containing 20% MSC qualified FBS (Life Technologies), 2% Penicillin Streptomycin (Life Technologies),1ng/ml murine basic fibroblast growth factor (Thermo Fisher Scientific) and 5ng/ml murine epidermal growth factor (Peprotech). To study the effect of TGFb or CXCL4, primary Gli1 + BM cells were seeded at a density of 60.000 cells/well in 6-well plates and cytokine treatment was started 24h later. The cytokines were added in fresh medium every 24 hr, for a total of 72 hr, at the following concentrations: TGFb1 (100-21-10UG, Peprotech) 10ng/ml, CXCL4 (795-P4-025, R&D Systems) 400ng/ml. PBS (solvent for TGFb) and DMSO (solvent for CXCL4) were added as controls. After 72 hr cells were subjected to flow cytometry for a-SMA as described below.
Viral transduction
For retro-and lentiviral transductions, ckit + cells from WT littermates were isolated using the autoMACS pro Separator after crushing the compact bone (Miltenyi Biotec). Ckit + BM cells were pre-stimulated for 24 hr in StemSpan Serum-Free Expansion Medium (Stem Cell Technology, Vancouver, Canada) supplemented with murine thrombopoietin (m-tpo) (50 ng/mL; Peprotech), murine stem cell factor (m-scf) (50 ng/mL; Peprotech). Oncoretroviral vectors were pseudotyped with ecotropic envelope and produced using standard protocols. Retroviral transduction was performed on retroNectin (Takara Bio) coated cell culture dishes loaded with unconcentrated virus. Cells were then resuspended in virus containing medium in the presence of 4 mg/ml polybrene (final concentration).
Lentiviral particles were produced by transient transfection with lentiviral plasmid together with pSPAX and VSVG packaging plasmids using TransIT-LT (Mirus). Lentiviral and retroviral particles were concentrated using ultracentrifugation. Lentiviral transduction was performed with concentrated lentiviral supernatant in the presence of 4 mg/ml Polybrene using spin-infection for 90 min at 2,200rpm at 37 C.
Co-culture of HSCs and MSCs
For co-culture of Gli1 + stromal cells with c-kit+ hematopoietic stem and progenitor cells expressing control cDNA or ThPO/ Jak2(V617F), c-kit+ cells were isolated and pre-stimulated for 24 hr in StemSpan Serum-Free Expansion Medium (Stem Cell Technology, Vancouver, Canada) supplemented with murine thrombopoietin (m-tpo) (50ng/mL; Peprotech), and murine stem cell factor (m-scf) (50ng/mL; Peprotech). C-kit cells were then transduced with concentrated lentivirus and 4mg/ml polybrene for 24 hr. Next, the cells were washed and co-cultured with Gli1 + stromal cells which were seeded at a density of 50 000 cells/well in alpha MEM (GlutaMAX, Life Technologies) containing 10% MSC qualified FBS (Life Technologies). For the analysis of stromal cells, hematopoietic cells were washed away (or harvested) and stromal cells were recovered by trypsinization. For the GANT61 experiments cells were treated for the last 48h with 10mM GANT61 in DMSO versus vehicle (DMSO) alone.
Migration assay
Lentivirally transduced c-kit + cells from WT littermates of Gli1CreER;tdTomato mice were seeded at 50,000 cells/well in a 24 well plates 24 hr after transduction. Primary Gli1 + BM cells were seeded at 50,000 cells/well in transwells of the InnoCyte Cell Migration Assay (Millipore, #CBA017) above the ckit+ cells (bottom well). Cell migration was measured by flow cytometry of cells in the bottom well. Alpha MEM (GlutaMAX, Life Technologies) containing 20% MSC qualified FCS (Life Technologies), 2% Penicillin Streptomycin (Life Technologies) was used as medium in this system.
In another set of experiments, solely Gli1 + cells were cultured in the transwell (600,000 cells/well) and recombinant Cxcl4 (95-P4-025, R&D Systems) in DMSO was added at 400ng/ml to the medium in the bottom well versus DMSO alone. After 12 hr of incubation, cell migration was measured by either flow cytometry or according to the manufacturer's instructions on a plate reader (BMG Labtech, Clariostar).
Cytokine array C-kit+ HSC were isolated from 8 week old WT C57Bl6/J mice (males) as described above and lentivirally or retrovirally transduced with ThPO or Jak2(V617F) versus controls (empty backbone or WT Jak2, respectively). Cells were cultured in StemSpan serum-free expansion medium (Stem Cell Technology, Vancouver, Canada) supplemented with murine thrombopoietin (m-tpo) (50ng/mL; Peprotech), and murine stem cell factor (m-scf) (50ng/mL; Peprotech). After 7 days the cells were washed 3 times in PBS and starved in RPMI (GIBCO) with 0.5% MSC-FCS (Life Technologies). The supernatant was harvested and incubated with the membranes of the mouse cytokine array (C2000 AAM-CYT-2000-2, Ray Biotech) according to the manufacturer's instructions. Imaging was achieved by chemiluminescence detection with the ChemiDoc imager (BioRad) and quantification by analyzing the pictures with the Protein Array Analyzer plugin for ImageJ.
RNA-Sequencing and bioinformatics
For RNA-Sequencing 6-7 week old bigenic Gli1CreER;tdTomato mice were injected with tamoxifen (3x10mg p.o.), subjected to lethal irradiation 10 days after the last tamoxifen dose and received BM of wild-type littermates that had been transduced with ThPO or control (empty backbone) lentivirus as described above. 10 weeks after BM transplantation mice were sacrificed, whole BM samples were lineage-depleted using paramagnetic microbeads and an autoMACS pro magnetic separator (Miltenyi Biotec). Gli1 + cells were sorted as lineage -, GFP -, tdTomato + on a FACS Aria II (BD Bioscience) into PBS (5% FBS) and frozen in liquid nitrogen as pellets. RNA was extracted using TRIZOL Reagent (Life Technologies) according to the manufacturer's instructions. cDNA libraries were generated using the Smart-Seq V4 ultra low input RNA kit (Clontech Laboratories) according to manufacturer instructions. Subsequently, amplified cDNA libraries were further processed using the Truseq Nano DNA sample prep guide (Illumina) generating Illumina Hiseq compatible pooled libraries that were sequenced paired-end (2x75 cycles) on a Hiseq2500 platform (Illumina). The unprocessed data resulting from Hiseq2500 (Illumina) were demultiplexed using casava (Illumina). Quality metrics of the resulting fastq files were measured using the programs fastqc (Babraham bioinformatics) and multiqc (http://multiqc.info). The later program summarizes the result of the first. An insert size estimate was performed by aligning the reads to a reference transcriptome using BWA (http://bio-bwa.sourceforge.net) and the actual insert size estimate was done with the program collectInsertSizeMetrics from the picard tools suite. The splicing aware alignment was performed using Tophat2 (https://ccb.jhu.edu/software/tophat/index. shtml) using the previously computed estimate for the insert size. Prior to the alignment the SMARTer adapters were trimmed. Gene and isoform abundance estimation was performed using cufflinks (http://cole-trapnell-lab.github.io/cufflinks/). Gene counts that were used in the differential expression analysis, clustering and principle component plots were obtained using HTseq counts (http://www-huber.embl.de/HTSeq/doc/count.html) using the intersect strict settings. Finally principle component analysis and clustering was performed using R (https://www.r-project.org/).
Directional pathway enrichment analysis was performed using the PIANO R package (Bioconductors, https://bioconductor. org/packages/release/bioc/html/piano.html, (V€ aremo et al., 2013) and a collection of pathway adapted to Mus musculus (GSKB R package, Bioconductors, https://bioconductor.org/packages/release/data/experiment/html/gskb.html). PIANO compute the significance of the directional enrichment of a pathway by aggragating (here through the median) the FDR corrected p values yielded by a set of enrichment methods. The method used here are: mean, median, sum, maxmean, stoufer, fisher, tail strength, wilcoxon and PAGE. The detailed explanation of the different methods can be found in (V€ aremo et al., 2013) . The collection of pathway used here as gene sets is derived from MSigDB canonical pathway complemented by a few other currated pathway databases and metabolic reaction networks (see GSKB R package). Reactome was discarded from the pathway sources as it was too much redundant with itself and other pathway ressources. The script of the pathway enrichment analysis is available at https://github.com/ adugourd/PIANO_kramann_2017.
Flow cytometry BM cells were isolated by flushing and crushing pelvis and hind leg bones with PBS (GIBCO) + 2% FBS + Penicillin/Streptomycin (GIBCO). Whole BM was lysed on ice with red blood cell (RBC) lysis solution (Invitrogen/Life Technologies), and washed in PBS (GIBCO) + 2% FBS. Single-cell suspensions of spleen were prepared by pressing tissue through a cell strainer followed by red blood cell lysis. Cells were labeled with the following monoclonal, directly fluorochrome conjugated antibodies: anti-mouse: Ter119 (eBioscience efluor 450), Gr1 eBioscience (efluor 450), CD11b (eBioscience, efluor 450), B220 (efluor 450 eBioscience), CD3 (efluor 450 eBioscience), CD150 (PeCy7 BioLegend), CD48 (APCCy7 Biolegend), CD34 (Alexa Fluor 700 eBioscience), ckit (APC eBioscience), Sca1 (PE, eBioscience), Gr1 (Alexa Fluor 700, eBioscience), CD11b (APC, eBioscience), CD3 (PE, eBioscience), CD19 (PeCy7 eBioscience), Ter119 (FITC, eBioscience), CD31 (APC, Biolegend), CD34 (FITC, eBioscience), CD29 (APC, eBioscience), Sca1 (APC-Cy7, Biolegend), CD44 (PE-Cy7 eBioscience); CD105 (PE-Cy7, Biolegend), CD73 (APC, Biolegend), PDGFRa (APC, Biolegend), CD31 (APC, Biolegend), CD34 (FITC, eBioscience), CD29 (APC, eBioscience), Sca1 (APC-Cy7, Biolegend), CD44 (PE-Cy7 eBioscience); CD105 (PE-Cy7, Biolegend), CD73 (APC, Biolegend), PDGFRa (APC, Biolegend). Antihuman: CD90 (PeCy7, BD PharMingen), CD105 (V450, BDPharmingen), Nestin (PE, RnD Systems). Further the following primary non-conjugated antibodies were used: Nestin (1:100, Abcam), CD51 (1:100, Biolegend), aSMA (1:100 Sigma), Gli1 (1:100, Novus biological). For flow cytometry, cells were stained in antibodies diluted as 1:100 in 2% FBS/PBS for 30 min on ice.
The staining of the intracellular antigens was performed after fixation and permeabilization of the cells (Cytofix/Cytoperm solution, BD Biosciences). Following incubation with primary antibodies, cells were washed in PBS and incubated with the appropriate AF647/ AF488 secondary antibodies (Jackson Immuno) at 1:200 for 15min on ice. For detection of apoptosis, the APC Annexin V antibody (BD Bioscience, #550474) was used together with the Annexin V Binding Buffer (BD Bioscience, #556454) and co-staining for DAPI or 7AAD (BD Bioscience, #559925) was performed according to the manufacturer's instructions. For staining of pSTAT5, cells were fixed in 4% paraformaldehyde (Sigma) for 10 min followed by permeabilization with 90% ice cold methanol (Sigma) for 30 min followed by staining with the pSTAT5 antibody (PE-Cy7, 1:100, BD Bioscience #560117) in PBS. To increase the flow efficiency, whole BM samples were lineage-depleted (for HSC staining and stromal cells) or -enriched (lineages) using paramagnetic microbeads and an autoMACS pro magnetic separator (Miltenyi Biotec). All flow cytometric analyses were performed at the LSR II Flow Cytometer or Canto II (both BD Biosciences). For flow cytometric analyses DAPI (1mg/ml 1:1000) was added in order to exclude dead cells. Data were analyzed by using Flow Jo software (Version 9.6.2, Tree Star Inc).
Viral vector cloning
The murine Jak2 cDNA was cloned into the retroviral vector MSCV-IRES EGFP (a gift from Tannishtha Reya Addgene #20672). The V617F mutation in Jak2 was achieved using site-directed mutagenesis (Quikchange-XL; Agilent). The murine Thrombopoietin cDNA (MGC clone 3593885, GE Dharmacon) was PCR amplified using the primer sequences 5 0 -AGACCGGTGCCACCATGGAGCTGACT GATTTGCTCC-3 0 and 5 0 -TCACGCGTCTATGTTTCCTGAGACAAATTCC-3 0 . Subsequently, the PCR product was digested with AgeI and XhoI and cloned into the pRRL.PPT.SFFV.IRES2.EGFP.PRE (kindly provided by A. Schambach and C. Baum, Hannover Medical School, Hannover, Germany).
Histological an immunohistochemical analysis
For histological and immunohistochemical analyses, murine organs were fixed in 4% formaldehyde overnight, dehydrated and prepared for paraffin embedding. H&E staining and reticulin staining was done according to routine protocols. Human BM biopsies were fixed for 24 hr using 12% buffered formaldehyde plus 64% methanol, decalcified (EDTA), dehydrated and embedded in paraffin. For immunohistochemistry, samples were deparaffinized and stained as follows.
Immunohistochemical analysis was performed using a primary antibody for Gli1 (Novus biological, NG-600-600, 1:100). Antigen demarcation was achieved by pressure cooker treament in citrate buffer (Vector Antigen unmasking solution). After blocking (Blocking Kit; Vector Laboratories) and 3%H2O2 treatment, sections were incubated with the primary antibody. Biotinylated monoclonal goat-anti-rabbit (Vector Laboratories) was used as a secondary antibody. Detection was performed using the Vectastin ABC Kit (Vector Laboratories). Slides were counterstained with hematoxylin. Cell numbers and co-staining was evaluated in 400x magnification at the Keyence BZ9000 by a blinded pathologist. Co-staining by immunohistochemistry in human BM biopsies was achieved by using the regular staining as described above for the first antigen (Leptin Receptor, 1:100, Santa Cruz sc-1834; Nestin 1:100, Abcam Ab134017; NG2 1:100, Millipore AB5320) followed by staining of the second antigen (Gli1 1:100, Novus biological, NG-600-600) with the ImmPRESS-AP Anti Rabbit IgG (alkaline phosphatase) polymer detection kit (Vector MP-5401) and the Vector Red Alkalkine Phosphatase (Red AP) Substrate Kit (#SK5100).
For immunofluorescence studies, tissue was fixed in 4% paraformaldehyde on ice for 1 hr, then incubated in 30% sucrose in PBS at 4 C overnight. OCT-embedded (Sakura Finetek) tissues were cryosectioned into 6mm sections and mounted on Superfrost slides (Fisher Scientific). Sections were washed in 1X PBS, blocked in 10% normal goat serum (Vector Labs) and incubated with primary antibodies specific for alpha SMA (1:200, Sigma, # A2547), CD31 (1:100, ebioscience, #14-0311 and AF3628 1:100 R&D Systems), leptin receptor (1:100; sc-1834, Santa Cruz), CD105 (1:100, MAB 1320, R&D Systems), Nestin (1:100, abcam ab134017), NG2 (AB5320 Millipore tyrosine hydroxylase (1:100, #AB152 millipore), GFAP (1:100; DAKO Z0334). Secondary antibodies were FITC-, or Cy5-conjugated (Jackson ImmunoResearch). To stain lipid droplets OCT sections were incubated with LipidTox Deep Red neutral lipid stain (Invitrogen, H34477) at 1:200 in PBS for 1 hr. To stain bone, we used Fetuin A from fetal bovine serum (Sigma aldrich #F2379) which was purified over HiLoad 16/60 Superdex 200pg columns (GE Healthcare #28989335) in an Ä KTA Purifier (GE Healthcare #28406264) and then conjugated with Alexa Fluor 647 NHS Ester (Invitroagen #A37573), according to the manufacturer's instructions. All sections were counterstained with DAPI (4 0 ,6 0 -0 diamidino-2-phenylindole) and mounted in Prolong Gold (Life Technologies). Images were obtained by confocal microscopy (Nikon C1 eclipse and Zeiss LSM 710).
Clearing and imaging of mouse bone Solvent-based optical clearing was performed using a sequence of dehydration steps in ethanol (50% for 12 hr, 70% for 6 hr, and 100% for 6 hr), followed by direct immersion on ethyl cinnamate (Sigma, #112372) for 12 hr in order to render the bone transparent. Vasculature was labeled with a CD31-AF647 antibody (BioLegend, #102516). Imaging was performed using an upright scanning confocal microscope (Leica TCS SP8; Leica Microsystems, Wetzlar, Germany). Optical sections were acquired with an optimized step-size of 2 mm for a total depth of 120 mm. Image post-processing and 3D rendering was performed with Imaris (Bitplane, v8.1).
Real Time PCR Experiments
Tissue was harvested and immediately snap frozen in liquid nitrogen. RNA from was extracted according to the manufacturer's instructions using the RNeasy Mini Kit (QIAGEN) and 600ng of total RNA was reverse transcribed with iScript (BioRad). During the RNA extraction DNA was removed by a DNase digestion step (Life Technologies). Quantitative polymerase chain reactions were carried out with iQ-SYBR Green supermix (BioRad) and the Applied Biosystems, 7300 Real-Time PCR System. Cycling conditions were 95 C for 3 min then 40 cycles of 95 C for 15 s and 60 C for 1 min, followed by one cycle of 95 C for 10 s. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a housekeeping gene. Data were analyzed using the 2 -DDct method. Primers are listed in Tables S3 and S4.
Immunocytochemistry
Human MSCs (n = 4 healthy; n = 4 MPN patients) were seeded at a density of 1x10 5 cells/well in chamber slides (Nunc, lab tek, Thermo Fischer Scientific, Darmstadt, Germany), the next day cells were treated for 24 hr with 10 mM Gant61 (Sigma, Munich, Germany). After washing and fixation steps, cells were stained with a-SMA antibody (Sigma, Munich, Germany) at 1:400 for 3h at RT, and co-stained with the fluorescent secondary-labeled antibody donkey anti-mouse Alexa Fluor 488 (Thermo Fischer Scientific, Darmstadt, Germany) at 1:200 for 1h at RT. After washing, cells were stained with the primary unconjugated antibody Gli1 (Novus Biologicals, Wiesbaden Nordenstadt, Germany) at 1:100 overnight at 4 degree and stained with the fluorescent secondary-labeled antibody goat anti-rabbit Alexa Fluor 633 (Thermo Fischer Scientific, Darmstadt, Germany) at 1:200 for 1h at RT. Nuclear staining was performed with DAPI at 1 mg/mL for 15 min at RT and mounting with Vectashield (#H-1000, Biozol, Eching, Germany). Images were acquired with a confocal laser scanning microscope (LSM 710; Zeiss, Germany) running the Zen 2012 (Zeiss) software.
Image Quantification
The distance to either CD31 + endothelial cells or Fetuin A + bone was performed by ImageJ. Random images were acquired by the LSM710 confocal microscope (Zeiss) with a magnification of 800x (at least 3-4 images of 3 mice per group). All images were processed by ImageJ. First, all images were split into RGB channels. Gaussian blur was applied to adjust background noise in all channels. Auto-threshold was used to convert intensity values of CD31 staining and tdTomato + area into binary data. Then a distance map was created from the binary data. One maximum intensity point was selected as the representative point of each nucleus. These points were used to divide the binary tdTomato + area into smaller areas representing single tdTomato + cells. Selected nuclei and the divided tdTomato + areas were overlayed on a CD31 or Fetuin A generated distance map. The distance value from each nucleus to the nearest CD31 or Fetuin A positive area was calculated. Quantification of GFAP + and tyrosine hydroxylase + areas was performed by ImageJ using the Gaussian blur and auto-threshold function. The number of tdTomato + , aSMA + and aSMA + /tdTomato + cells were calculated by ImageJ using split single channels (RGB). Auto-threshold was again used to identify aSMA + and tdTomato + binary area and the overlying point of maximal intensity of each nucleus was used to quantify the number of each cell population. CD31 surface area from immunohistochemistry was calculated using the number of stained pixels per total pixels in Adobe Photoshop CS5 (Adobe Systems Inc.). Reticulin staining (MF grade) was quantified by a blinded hematopathologist based on the WHO criteria. Gli1 + cells in human BM biopsies were counted by a blinded hematopathologist in at least 3 random high power fields (400x) per patient. The association to bone and vasculature was noted during counting. Gli1-tdTomato + cell distribution and co-localization with marker expression was counted in backbone and sternal bone sections (at least 4/mouse) using the LSM710 confocal microscope.
QUANTIFICATION AND STATISTICAL ANALYSIS
Data are presented as mean ± SEM. Comparison of two groups was performed using unpaired t test. Paired t test was used for comparison of repeated-measures in the same group. For multiple group comparison analysis of variance with posthoc Tukey correction was applied. Statistical analyses were performed using GraphPad Prism 5.0c (GraphPad Software Inc., San Diego, CA). A p value of less than 0.05 was considered significant.
DATA AND SOFTWARE AVAILABILITY
The accession number for the RNA sequencing data reported in this paper is EBI: ERA829202.
